Details for Patent: 4,385,048

Summary for Patent: 4,385,048

Title:	Methods for the treatment of nasal hypersecretion
Abstract:	Compositions for the treatment of nasal hypersecretion comprising (8r)-8-isopropyl-3 alpha -[(+/-)-tropoyl-oxy]-1 alpha H, 5 alpha H-tropanium bromide in a pharmaceutical formulation suitable for topical application to the nasal cavity; and methods of use.
Inventor(s):	Niels Mygind, Peter Borum, Christiane Grieben
Assignee:	Boehringer Ingelheim GmbH
Application Number:	US06/208,411
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

United States Patent 4,385,048 (US4385048) Scope, Claims, and Patent Landscape for Nasal Hypersecretion Inhibition

US 4,385,048 claims a method of treating nasal hypersecretion by topically administering to nasal mucosa a liquid-carrier nasal composition containing a specific tropine ester methobromide, “N-isopropyl-nortropine tropic acid ester methobromide.” The claims are drafted around (i) the therapeutic indication, (ii) topical administration to nasal mucosa, (iii) a “consisting essentially of” formulation restriction focused on an inert liquid carrier plus the active, and (iv) enumerated carrier embodiments (water; acidic aqueous surfactant solution; specific halocarbon propellant gas mixture with a surfactant) plus optional combination with fenoterol.

US 4,385,048 is a first-in-class “nasal anticholinergic-type” nasal hypersecretion inhibition method claim set, with secondary claim layers that narrow to specific carrier systems and one explicit co-ingredient (fenoterol).

---

What does US Patent 4,385,048 claim, and what is the claimed method of treating nasal hypersecretion?

Core claim theme: treat nasal hypersecretion by topically administering to nasal mucous membrane a nasal hypersecretion inhibiting amount of N-isopropyl-nortropine tropic acid ester methobromide in a topical pharmaceutical composition that is “consisting essentially of” an inert liquid carrier and the active.

Claim 1: the broadest operative scope

Claim 1 recites:

• Exerted activity: “method of treating nasal hypersecretion”
• Route/site: “topically administering to the nasal mucous membrane”
• Dose concept: “effective nasal hypersecretion inhibiting amount”
• Formulation restriction: “topical pharmaceutical composition consisting essentially of an inert liquid carrier suitable for topical administration to the nasal mucous membrane and an effective nasal hypersecretion inhibiting amount of”
  N-isopropyl-nortropine tropic acid ester methobromide

Interpretive pressure points for claim construction:

• “Nasal hypersecretion” is a functional disease descriptor. For infringement and freedom-to-operate, the claim is satisfied by use in that therapeutic context, not by a particular diagnostic definition.
• “Topically” and “to the nasal mucous membrane” limit the route to intranasal mucosal contact rather than systemic dosing.
• “Consisting essentially of” is central. It permits additional components only if they do not materially change the basic and novel characteristics of (1) inert liquid carrier suitable for nasal mucosa and (2) nasal hypersecretion inhibition by the claimed methobromide active.

Claims 2–4: carrier system-dependent scope narrowing

• Claim 2: inert liquid carrier is water.
• Claim 3: inert liquid carrier is an acidic aqueous solution of a surfactant.
• Claim 4: inert liquid carrier is a propellant gas mixture comprising:
  • monofluoro-trichloromethane
  • difluoro-dichloromethane
  • tetrafluoro-dichloromethane
    and the mixture comprises a surfactant.

These dependent claims create three distinct infringement entry points:

1. aqueous solutions,
2. acidic surfactant solutions,
3. pressurized propellant aerosol-like systems using the named halocarbon propellant trio and surfactant.

Claims 5–6: explicit combination layering

• Claim 5: composition additionally comprises another nasally active ingredient.
• Claim 6: the other nasally active ingredient is fenoterol.

This gives a straightforward combination infringement pathway: a nasal product containing the claimed active methobromide plus fenoterol in a compliant carrier system can fall within Claim 5/6 even if the “basic composition” requirement is otherwise met.

---

How broad is the “consisting essentially of” limitation in Claim 1, and what does it allow as extra ingredients?

Claim 1 allows additional components only if they do not materially change the basic and novel characteristics of the claimed composition: a nasal-compatible inert liquid carrier and effective nasal hypersecretion inhibition by N-isopropyl-nortropine tropic acid ester methobromide.

In practical landscape terms, this is the dividing line between:

• products that only add inert/compatible excipients that do not materially alter the carrier or functional delivery of the active, and
• products that add additional functional agents that change the composition’s basic characteristics (for example, an alternative active class, a different delivery mechanism that changes deposition or release properties, or excipients that materially alter the aerosolization/solution characteristics such that the “basic” formulation is different).

Because Claims 2–4 and 5–6 explicitly list carrier types and an optional co-therapy, any non-listed carriers or combinations face a higher bar to fit “consisting essentially of” under Claim 1, even if they could be argued to be “inert.”

---

Does US 4,385,048 cover aqueous intranasal solutions, acidic surfactant solutions, or propellant aerosols?

Yes. Claims 2–4 are carrier-specific.

Aqueous water carrier (Claim 2)

A product formulated as a nasal mucosal liquid where the inert liquid carrier is water is within Claim 2 if it includes the effective amount of the claimed active methobromide.

Acidic aqueous surfactant carrier (Claim 3)

A product where the inert liquid carrier is:

• acidic aqueous solution
• surfactant-present falls within Claim 3.

This claim is useful for product developers because it targets pH-dependent formulation space and surfactant-containing solution formulations.

Propellant gas mixture plus surfactant (Claim 4)

A formulation using the specified halocarbon propellant trio, including surfactant, is within Claim 4:

• monofluoro-trichloromethane
• difluoro-dichloromethane
• tetrafluoro-dichloromethane

This claim is tightly drafted to the named propellants rather than to a generic “CFC/HFC propellant” class, which materially narrows coverage to that specific propellant set unless doctrine-of-equivalents or alternative claim construction applies.

---

What is the scope of the fenoterol combination coverage (Claims 5–6)?

Claim 6 is explicit: the other nasally active ingredient is fenoterol.

That gives a clean infringement theory for intranasal products that contain:

• N-isopropyl-nortropine tropic acid ester methobromide, and
• fenoterol, in a topical nasal liquid formulation that meets the “consisting essentially of” requirement and is administered to nasal mucous membrane for nasal hypersecretion treatment.

Claim 5 is broader than Claim 6 because it only requires “another nasally active ingredient” without naming it. Claim 6 then narrows that “other” ingredient to fenoterol.

In a freedom-to-operate context, the most conservative risk posture is for any intranasal dual-activity product combining this active methobromide with fenoterol in an at least substantially similar liquid-carrier system.

---

What types of infringing products are covered by US 4,385,048, and what design-arounds exist within the claim language?

Potentially covered product profiles

1. Intranasal solution with water as inert carrier + the methobromide active.
2. Intranasal acidic aqueous surfactant solution + methobromide active.
3. Pressurized intranasal aerosol-like formulations using the named propellant gas mixture + surfactant + methobromide.
4. Intranasal formulation with methobromide active plus fenoterol (with a carrier that satisfies Claim 1’s “consisting essentially of” constraint).

In-claim design pressure points

• Route and site: any formulation intended for systemic delivery or non-mucosal delivery is outside the claim.
• Formulation constraint: changing from “inert liquid carrier” to a non-liquid or non-inert system risks leaving the claim, depending on how “liquid carrier” and “consisting essentially of” are construed.
• Carrier-specific dependent claims: Claim 2–4 narrow to specific carrier embodiments; a carrier outside those enumerations would still potentially be tested under Claim 1, but infringement risk drops if the formulation departs from “inert liquid carrier” characteristics.
• Propellant specificity: changing the propellant to a non-named propellant can avoid Claim 4.
• Fenoterol specificity: removing fenoterol eliminates Claim 6, but not necessarily Claim 5 unless the product uses an “other nasally active ingredient” that still fits the claim.

---

Which competitors or generics could be at risk under US 4,385,048’s claimed method and formulation scope?

This question cannot be answered completely from the claim text alone. A correct competitor risk assessment requires mapping:

• the identity of the active ingredient in competing intranasal products,
• their carrier system (water, acidic surfactant solution, or propellant aerosol with the named gas mixture),
• whether fenoterol is included,
• and whether the product is marketed for “nasal hypersecretion” treatment.

Because those mapping facts are not provided here, the only defensible landscape statement is claim-based: any intranasal nasal hypersecretion product containing the specified methobromide active, delivered to nasal mucosa in an inert liquid carrier system, falls within Claim 1, and the carrier/fenoterol embodiments fall within Claims 2–4 and 6 if they match exactly.

---

What patent-expiration and exclusivity issues arise for US 4,385,048 in the United States?

A complete exclusivity and expiration timeline requires:

• the patent issue date,
• priority/filing date,
• whether it is subject to PTA (Patent Term Adjustment),
• whether any terminal disclaimer applies,
• and how it is tied to a specific FDA approval and Orange Book listings.

The claim text provided does not include the key bibliographic data required for a correct expiration analysis. A precise “when does it lose exclusivity” answer therefore cannot be produced from the information supplied.

---

How strong is the enforceability of US 4,385,048: key validity and claim-scope risk points?

From claim language alone, the enforceability strengths and vulnerabilities can be framed as follows:

Strengths

• Specific chemical identity: the active is named as “N-isopropyl-nortropine tropic acid ester methobromide,” which can reduce invalidity risk based on overbreadth at the active-ingredient level.
• Clear route/site: “topically administering to the nasal mucous membrane” provides a direct infringement hook.
• Carrier embodiments are concrete: Claims 2–4 narrow dependent scope and can support clear infringement allegations for matching product forms.

Vulnerabilities

• “Consisting essentially of” ambiguity: The scope turns on what counts as materially changing basic and novel characteristics. In litigation, this can create factual disputes over formulation components and whether they materially affect the formulation’s basic properties.
• Functional disease claim: “nasal hypersecretion” is a functional term. If a product is used for different nasal conditions, the method claim’s medical indication may be contested as to infringement.

---

How do you map US 4,385,048 to likely Orange Book or FDA listings?

Orange Book mapping requires the specific drug product name and the approved formulation details. The claim text does not provide the FDA application number, NDA/BLA designation, dosage form name, or Orange Book listed active ingredient spelling that would enable deterministic mapping.

Accordingly, Orange Book status and listing-based generic entry risk cannot be concluded solely from the provided claim excerpt.

---

Key Takeaways

• US 4,385,048 Claim 1 is a method-of-use claim: intranasal treatment of nasal hypersecretion by delivering N-isopropyl-nortropine tropic acid ester methobromide in a liquid inert carrier composition that is “consisting essentially of” the carrier plus the active.
• Claims 2–4 narrow to specific carrier formats: water, acidic aqueous surfactant solution, and a named propellant gas mixture with surfactant.
• Claims 5–6 add combination scope: the composition can include another nasally active ingredient, and Claim 6 expressly covers fenoterol.
• For freedom-to-operate, the decisive elements to test against are: active identity, intranasal mucosal delivery, nasal hypersecretion indication, and the carrier system (especially the named propellants and fenoterol inclusion).

---

FAQs

1. Does US 4,385,048 require an aerosol propellant to infringe?
   No. Claim 1 covers topical intranasal liquid compositions broadly, and dependent Claims 2 and 3 cover water and acidic aqueous surfactant solutions.

2. Is fenoterol required for infringement of the broadest claim?
   No. Fenoterol is required only for Claim 6; Claim 1 can be infringed without fenoterol if it meets the carrier and active delivery requirements.

3. Can a product with a different propellant avoid Claim 4 but still risk Claim 1?
   Yes. Avoiding Claim 4 may reduce risk if the carrier is outside the specific propellant embodiment, but Claim 1 could still apply if the product meets the “consisting essentially of” requirement and uses the inert liquid carrier concept.

4. What is the most likely litigation dispute point in Claim 1?
   The scope of “consisting essentially of” and whether additional formulation components materially alter the basic characteristics of the inert liquid carrier plus active system.

5. Would a systemic formulation of the same active avoid the patent?
   Yes for infringement of these claims, because the claims require topical administration to the nasal mucous membrane.

---

References (APA)

1. U.S. Patent 4,385,048.

Drugs Protected by US Patent 4,385,048

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 4,385,048

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	2903957	Feb 02, 1979

International Family Members for US Patent 4,385,048

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	4865079
Australia	530174
Germany	2903957
New Zealand	190897